UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to________________

ARYA SCIENCES ACQUISITION CORP V

(Exact name of registrant as specified in its charter)

Cayman Islands	001-40595	98-1590338
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

51 Astor Place, 10th Floor New York, NY		10003
(Address Of Principal Executive Offices)		(Zip Code)

(212) 284-2300

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Ordinary Share, $0.0001 par value	ARYE	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of ~~November~~May 712, ~~2022~~2023, 15,449,000 Class A ordinary shares, par value $0.0001 per share, and 3,737,500 Class B ordinary shares, par value $0.0001 per share, were issued and outstanding.

ARYA SCIENCES ACQUISITION CORP V

Form 10-Q

For the Quarter Ended ~~September~~March 3031, ~~2022~~2023

Table of Contents

		Page
PART I. FINANCIAL INFORMATION
Item 1.	Condensed Financial Statements	1
	Condensed Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021	1
	Condensed Balance Sheets as of March 31, 2023 (unaudited) and December 31, 2022	1
	Unaudited Condensed Statements of Operations for the three and nine months ended September 30, 2022 and for the three months ended September 30, 2021 and for the period from February 22, 2021 (inception) through September 30, 2021	2
	Unaudited Condensed Statements of Operations for the Three Months ended March 31, 2023 and 2022	2
	Unaudited Condensed Statements of Changes in Shareholders’ Equity (Deficit) for the three and nine months ended September 30, 2022 and for the three months ended September 30, 2021 and for the period from February 22, 2021 (inception) through September 30, 2021	3
	Unaudited Condensed Statements of Changes in Shareholders’ Deficit for the Three Months ended March 31, 2023 and 2022	3
	Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2022 and for the period from February 22, 2021 (inception) through September 30, 2021	4
	Unaudited Condensed Statements of Cash Flows for the Three Months ended March 31, 2023 and 2022	4
	Notes to Unaudited Condensed Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	24
Signature		25

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1.

Condensed Financial Statements

ARYA SCIENCES ACQUISITION CORP V

CONDENSED BALANCE SHEETS

	September 30,			December 31,
	March 31,			December 31,
	2022			2021
	2023			2022
	(unaudited)
Assets
Current assets:
Cash	$	~~419~~295,~~178~~974		$	~~775~~385,~~885~~187
Prepaid expenses		~~249~~130,~~375~~000			~~460~~157,~~995~~000
Total current assets		~~668~~425,~~553~~974			1542,~~236,880~~187
Investments held in Trust Account		~~150~~153,~~380~~294,~~215~~256			~~149~~151,~~530~~601,~~514~~721
Total Assets	$	~~151~~153,~~048~~720,~~768~~230		$	~~150~~152,~~767~~143,~~394~~908
Liabilities and Shareholders’ Deficit
Current liabilities:
Accounts payable	$	12,~~741~~974		$	1211,~~663~~466
Accrued expenses		2,~~702~~830,~~928~~329			2,~~703~~776,~~653~~182
Due to related party		60120,000			-90,000
Total current liabilities		2,~~775~~963,~~669~~303			2,~~716~~877,~~316~~648
Deferred underwriting commissions		2,616,250			52,~~232~~616,~~500~~250
Total Liabilities		5,~~391~~579,~~919~~553			75,~~948~~493,~~816~~898
Commitments and Contingencies
Class A ordinary shares subject to possible redemption; 14,950,000 shares at redemption value of $10.05 and $10.00 per share at September 30, 2022 and December 31, 2021, respectively		150,280,215			149,500,000
Class A ordinary shares subject to possible redemption; 14,950,000 shares at redemption value of approximately $10.25 and $10.13 per share at March 31, 2023 and December 31, 2022, respectively		153,194,256			151,501,721
Shareholders’ Deficit:
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding		-			-
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding at March 31, 2023 and December 31, 2022		-			-
Class A ordinary shares, $0.0001 par value; 479,000,000 shares authorized; 499,000 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively		50			50
Class A ordinary shares, $0.0001 par value; 479,000,000 shares authorized; 499,000 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		50			50
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,737,500 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively		374			374
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,737,500 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		374			374
Additional paid-in capital		-			-
Accumulated deficit		(45,~~623~~054,~~790~~003	)		(64,~~681~~852,~~846~~135	)
Total shareholders’ deficit		(45,~~623~~053,~~366~~579	)		(64,~~681~~851,~~422~~711	)
Total Liabilities and Shareholders’ Deficit	$	~~151~~153,~~048~~720,~~768~~230		$	~~150~~152,~~767~~143,~~394~~908

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS

	For the three months ended September 30,						For the nine months ended September 30,			For the period from February 22, 2021 (inception) through September 30,
	For the Three Months Ended March 31,
	2022			2021			2022			2021
	2023			2022
General and administrative expenses	$	~~163~~201,~~022~~868		$	~~363~~228,~~776~~530		$	~~627,680~~		$	~~380,268~~
Loss from operations		(~~163~~201,~~022~~868	)		(~~363~~228,~~776~~530	)		~~(627,680~~	)		~~(380,268~~	)
Other income
Other income (expense)
Gain from settlement of deferred underwriting commissions		2,616,250			-			2,616,250			-
Unrealized gain (loss) on investments held in Trust Account		1,692,535			(49,628	)
Unrealized gain on investments held in Trust Account		661,899			14,533			849,701			14,533
Total other income (expense)		1,692,535			(49,628	)
Total other income		3,278,149			14,533			3,465,951			14,533
Net income (loss)	$	1,490,667		$	(278,158	)
Net income (loss)	$	3,115,127		$	(349,243	)	$	2,838,271		$	(365,735	)
Basic and diluted weighted average shares outstanding of Class A ordinary shares		15,449,000			15,449,000
Basic and diluted weighted average shares outstanding of Class A ordinary shares		15,449,000			13,098,065			15,449,000			6,116,863
Basic and diluted net income (loss) per share, Class A ordinary share	$	0.08		$	(0.01	)
Basic and diluted net income (loss) per share, Class A ordinary share	$	0.16		$	(0.02	)	$	0.15		$	(0.04	)
Basic and diluted weighted average shares outstanding of Class B ordinary shares		3,737,500			3,737,500
Basic and diluted weighted average shares outstanding of Class B ordinary shares		3,737,500			3,663,315			3,737,500			3,443,020
Basic and diluted net income (loss) per share, Class B ordinary share	$	0.08		$	(0.01	)
Basic and diluted net income (loss) per share, Class B ordinary share	$	0.16		$	(0.02	)	$	0.15		$	(0.04	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ ~~EQUITY (~~DEFICIT)

~~For~~FOR ~~the~~THE ~~three~~THREE ~~and~~MONTHS ~~nine~~ENDED ~~months~~MARCH ~~ended September 30~~31, ~~2022~~2023

	Ordinary Shares	~~Ordinary Shares~~																		Total	~~Total~~
	Class A	~~Class A~~					Class B	~~Class B~~					Additional Paid-in	~~Additional Paid-in~~		Accumulated	~~Accumulated~~			Shareholders’	~~Shareholder’s~~
	Shares	~~Shares~~		Amount	~~Amount~~		Shares	~~Shares~~		Amount	~~Amount~~		Capital	~~Capital~~		Deficit	~~Deficit~~			Deficit	~~Deficit~~
Balance - December 31, 2021			499,000		$	50			3,737,500		$	374		$	-		$	(6,681,846	)		$	(6,681,422	)
Balance - December 31, 2022			499,000		$	50			3,737,500		$	374		$	-		$	(4,852,135	)		$	(4,851,711	)
Net loss			-			-			-			-			-			(278,158	)			(278,158	)
Increase in redemption value of Class A ordinary shares subject to possible redemption			-			-			-			-			-			(1,692,535	)			(1,692,535	)
Balance - March 31, 2022 (unaudited)			499,000			50			3,737,500			374			-			(6,960,004	)			(6,959,580	)
Net income			-			-			-			-			-			1,490,667				1,490,667
Increase in redemption value of Class A ordinary shares subject to possible redemption			-			-			-			-			-			(118,316	)			(118,316	)
Balance - March 31, 2023 (unaudited)			499,000		$	50			3,737,500		$	374		$	-		$	(5,054,003	)		$	(5,053,579	)
Net income			-			-			-			-			-			1,302				1,302
Balance - June 30, 2022 (unaudited)			499,000			50			3,737,500			374			-			(7,077,018	)			(7,076,594	)
Increase in redemption value of Class A ordinary shares subject to possible redemption			-			-			-			-			-			(661,899	)			(661,899	)
Net income			-			-			-			-			-			3,115,127				3,115,127
Balance - September 30, 2022 (unaudited)			499,000		$	50			3,737,500		$	374		$	-		$	(4,623,790	)		$	(4,623,366	)

~~For~~FOR ~~the~~THE ~~three~~THREE ~~months~~MONTHS ~~ended~~ENDED ~~September~~MARCH 3031, ~~2021 and the period from February 22, 2021 (inception) through September 30, 2021~~2022

	Ordinary Shares	~~Ordinary Shares~~																			Total	~~Total~~
	Class A	~~Class A~~					Class B	~~Class B~~					Additional Paid-in	~~Additional Paid-in~~			Accumulated	~~Accumulated~~			Shareholders’	~~Shareholder’s~~
	Shares	~~Shares~~		Amount	~~Amount~~		Shares	~~Shares~~		Amount	~~Amount~~		Capital	~~Capital~~			Deficit	~~Deficit~~			Deficit	~~Equity (Deficit)~~
Balance - February 22, 2021 (inception)			-		$	-			-		$	-		$	-			$	-			$	-
Balance - December 31, 2021			499,000		$	50			3,737,500		$	374		$	-			$	(6,681,846	)		$	(6,681,422	)
Issuance of Class B ordinary shares to Sponsor			-			-			3,737,500			374			24,626				-				25,000
Net loss			-			-			-			-			-				(278,158	)			(278,158	)
Net loss			-			-			-			-			-				(9,290	)			(9,290	)
Balance - March 31, 2022 (unaudited)			499,000		$	50			3,737,500		$	374		$	-			$	(6,960,004	)			(6,959,580	)
Balance - March 31, 2021 (unaudited)			-			-			3,737,500			374			24,626				(9,290	)			15,710
Net loss			-			-			-			-			-				(7,202	)			(7,202	)
Balance - June 30, 2021 (unaudited)			-			-			3,737,500			374			24,626				(16,492	)			8,508
Sale of private placement shares to Sponsor in private placement			499,000			50			-			-			4,989,950				-				4,990,000
Accretion on Class A ordinary shares subject to possible redemption			-			-			-			-			(5,014,576	)			(3,694,578	)			(8,709,154	)
Net loss			-			-			-			-			-				(349,243	)			(349,243	)
Balance - September 30, 2021 (unaudited)			499,000		$	50			3,737,500		$	374		$	-			$	(4,060,313	)		$	(4,059,889	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS

	For the nine months ended September 30,			For the period from February 22, 2021 (inception) through September 30,
	For the Three Months Ended March 31,
	2022			2021
	2023			2022
Cash Flows from Operating Activities:
Net income (loss)	$	21,~~838~~490,~~271~~667		$	(~~365~~278,~~735~~158	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
General and administrative expenses advanced by related party		-			1,379
Unrealized (gain) loss on investments held in Trust Account		(1,692,535	)		49,628
Gain from settlement of deferred underwriting commissions		(2,616,250	)		-
Unrealized gain on investments held in Trust Account		(849,701	)		(14,533	)
Changes in operating assets and liabilities:
Prepaid expenses		~~211~~27,~~620~~000			~~(539~~36,~~723~~402	)
Accounts payable		781,508			~~156~~42,~~349~~603
Accrued expenses		~~(725~~54,147	)		-47,361
Due to related party		6030,000			-30,000
Net cash used in operating activities		(~~356~~89,~~707~~213	)		(~~762~~72,~~263~~164	)
Cash Flows from Investing Activities:
Net change in cash		(89,213	)		(72,164	)
Cash deposited in Trust Account		-			(149,500,000	)
Cash - beginning of the period		385,187			775,885
Net cash used in investing activities		-			(149,500,000	)
Cash - end of the period	$	295,974		$	703,721
Cash Flows from Financing Activities:
Proceeds from note payable to related party		-			150,000
Repayment of note payable and advances to related party		-			(151,379	)
Proceeds received from initial public offering, gross		-			149,500,000
Proceeds received from private placement		-			4,990,000
Offering costs paid associated with initial public offering		-			(3,381,654	)
Net cash provided by financing activities		-			151,106,967
Net change in cash		(356,707	)		844,704
Cash - beginning of the period		775,885			-
Cash - end of the period	$	419,178		$	844,704
Supplemental disclosure of noncash investing and financing activities:
Offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares	$	-		$	25,000
Offering costs included in accrued expenses	$	-		$	70,000
Deferred underwriting commissions	$	-		$	5,232,500

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Note 1 - Description of Organization and Business Operations

ARYA Sciences Acquisition Corp V (the “Company”) was incorporated as a Cayman Islands exempted company on February 22, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.

All activity for the period from February 22, 2021 (inception) through ~~September 30~~March 31, ~~2022~~2023 was related to the Company’s formation and the initial public offering (the “Initial Public Offering”) described below, and since the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.

The Company’s sponsor is ARYA Sciences Holdings V, a Cayman Islands exempted limited company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on July 12, 2021. On July 15, 2021, the Company consummated its Initial Public Offering of 14,950,000 Class A ordinary shares (the “Public Shares”), including the 1,950,000 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $149.5 million, and incurring offering costs of approximately $8.7 million, inclusive of approximately $5.2 million in deferred underwriting commissions (see Note 5). On August 8, 2022, the Company received a waiver from one of ~~its~~the underwriters of its Initial Public Offering pursuant to which such underwriter waived all rights to its 50% share of the deferred underwriting commissions payable upon completion of an initial Business Combination. In connection with this waiver, the underwriter also agreed that (i) this waiver is not intended to allocate its 50% portion of the deferred underwriting commissions to the other underwriter that has not waived its right to receive its share of the deferred underwriting commissions and (ii) the waived portion of the deferred underwriting commissions can, at the discretion of the Company, be paid to one or more parties or otherwise be used in connection with an initial Business Combination.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 499,000 Class A ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.0 million (see Note 4).

Upon the closing of the Initial Public Offering and the Private Placement, $149.5 million ($10.00 per Public Share) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (the “Trust Account”), located in the United States, with Continental Stock Transfer & Trust Company acting as trustee, and are invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the amount of deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

The Company will provide the holders of Public Shares (the “Public Shareholders”) ~~of Public Shares~~, with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially atanticipated to be $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).

These Public Shares were classified as temporary equity in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, only if a majority of the ordinary shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which the Company will adopt upon the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or vote at all. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders (as defined below) agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares ~~purchased~~they ~~during~~hold ~~or after the Initial Public Offering~~ in favor of a Business Combination. Subsequent to the consummation of the Initial Public Offering, the Company will adopt an insider trading policy which will require insiders to: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the initial shareholders agreed to waive their redemption rights with respect to their Founder Shares, Private Placement Shares and Public Shares in connection with the completion of a Business Combination.

Notwithstanding the foregoing, if the Company seeks shareholder approval of its Business Combination and does not conduct redemptions in connection with its Business Combination pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company.

The Company’s Sponsor, officers and directors (the “initial shareholders”) agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to provide holders of its Public Shares the right to have their shares redeemed in connection with a Business Combination or to redeem 100% of the ~~Company’s~~ Public Shares if the Company does not complete its Business Combination within 24 months from the closing of the Initial Public Offering, or July 15, 2023, (the “Combination Period”), or (b) with respect to any other provision relating to the rights of Public Shareholders, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment.

If the Company has not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

The initial shareholders agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the Company if and to the extent any claims by a third party (excluding the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions in the value of the assets in the Trust Account, in each case net of the interest that may be withdrawn to pay for the Company’s tax obligations. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).

Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (excluding the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. The Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. The Sponsor may not be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.

~~Liquidity and~~ Going Concern

As of ~~September~~March 3031, ~~2022~~ 2023, the Company had approximately $~~419~~296,000 in its operating bank account, and working capital deficit of approximately $2.16 million.

The Company’s liquidity needs to date have been satisfied through a contribution of $25,000 from the Sponsor to cover for certain ~~offering~~expenses ~~costs~~ in exchange for the issuance of the Founder Shares, the loan of approximately $151,000 from the Sponsor pursuant to the Note (as defined in Note 4) and advances from the Sponsor, and $2 million in proceeds from the consummation of the Private Placement not held in the Trust Account. The Company fully repaid the Note on July 15, 2021. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 4). As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, there were no amounts outstanding under any Working Capital Loan.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

The Company cannot provide any assurance that new financing along the lines detailed above will be available to it on commercially acceptable terms, if at all. Further, the Company has until July 15, 2023 to consummate a Business Combination, but the Company cannot provide assurance that it will be able to consummate a Business Combination by that date. If a Business Combination is not consummated by the required date, there will be a mandatory liquidation and subsequent dissolution. In connection with the Company’s assessment of going concern considerations in accordance with FASB ASC Topic 205-40, “Basis of Presentation - Going Concern,” management has determined that the working capital deficit and liquidity conditions raise substantial doubt about the Company’s ability to continue as a going concern until the earlier of the consummation of the Business Combination or the date the Company is required to liquidate, July 15, 2023. The unaudited condensed financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The Company intends to complete its initial ~~business combination~~Business Combination before the mandatory liquidation date; however, there can be no assurance that the Company will be able to consummate any ~~business~~Business ~~combination~~Combination by July 15, 2023. No adjustments have been made to the carrying amounts of assets and liabilities should the Company be required to liquidate after July 15, 2023, nor do these unaudited condensed financial statements include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Risks and Uncertainties

Results of operations and the Company’s ability to complete a Business Combination may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond its control. The Company’s business of pursuing and consummating an initial Business Combination could be impacted by, among other things, downturns in the financial markets or in economic conditions, export controls, tariffs, trade wars, inflation, increases in interest rates, supply chain disruptions, declines in consumer confidence and spending, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflict in the Ukraine. The Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may materially impact the Company’s business and its ability to complete an initial Business Combination.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these unaudited condensed financial statements as they are not required for unaudited interim condensed financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three ~~and nine~~ months ended ~~September~~March 3031, 2023 ~~2022~~ are not necessarily indicative of the results that may be expected through December 31, ~~2022~~2023 or any future periods.

The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2022 and filed by the Company with the SEC on ~~March~~April 3112, ~~2022~~2023.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Concentration of ~~Credit~~Cash ~~Risk~~Balances

~~Financial~~The ~~instruments that potentially subject the~~ Company tohas ~~concentrations~~significant ~~of credit risk consist of~~ cash ~~accounts~~balances inat a financial institutions ~~institution,~~ which, atthroughout ~~times,~~the ~~may~~year regularly exceed the ~~Federal~~federally ~~Deposit~~insured ~~Insurance Corporation coverage~~ limit of $250,000. AsAny ofloss ~~September~~incurred ~~30,~~or ~~2022~~a ~~and~~lack ~~December~~of ~~31,~~access ~~2021,~~to ~~the~~such ~~Company~~funds ~~has~~could ~~not~~have ~~experienced~~a ~~losses~~significant onadverse ~~these accounts~~impact ~~and~~on ~~management believes~~ the Company’s isfinancial ~~not~~condition, results ~~exposed~~of tooperations, ~~significant~~and ~~risks~~cash ~~on such accounts~~flows.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, aside from the cash maintained in the Trust Account (see Note 8).

Use of Estimates

~~The~~ The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets liabilities and expenses and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements. Actual results could differ from those estimates.

Investments Held in Trust Account

The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in ~~net~~interest income and unrealized gain on investments held in Trust Account in the accompanying unaudited condensed statements of operations. The ~~estimated~~ estimated fair values of investments held in the Trust Account are determined using available market information.

Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” equals or approximates the carrying amounts represented in the condensed balance sheets.

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

•	Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

•	Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

•	Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, the carrying values of cash, accounts payable, accrued expenses and due to related party approximate their fair values due to the short-term nature of the instruments. The Company’s ~~marketable~~investments ~~securities~~ held in Trust Account are comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less and are recognized at fair value. The fair value of ~~marketable~~investments ~~securities~~ held in Trust Account is determined using quoted prices in active markets.

Offering Costs Associated with the Initial Public Offering

Offering costs consisted of legal, accounting, underwriting and other costs incurred that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with the Class A ordinary shares issued were charged against the carrying value of the Class A ordinary shares subject to possible redemption upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Class A Ordinary Shares Subject to Possible Redemption

The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ ~~equity (~~deficit). The Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, 14,950,000 Class A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ ~~equity (~~deficit) section of the Company’s condensed balance sheets.

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of the Class A ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

Income Taxes

FASB ASC Topic 740, “Income Taxes,” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

There is currently no taxation imposed on income by the government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Net Income (Loss) per Ordinary Share

The Company has two classes of shares: Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted-average number of ordinary shares outstanding during the periods. Accretion associated with the Class A ordinary shares subject to possible redemption is excluded from earnings per ordinary share as the redemption value approximates fair value.

	For the Three Months Ended September 30, 2022				For the Nine Months Ended September 30, 2022
	For the Three Months Ended March 31,
	2023				2022
	Class A		Class B		Class A			Class B
Basic and diluted net income (loss) per ordinary share:
Numerator:
Allocation of net income (loss)	$	21,~~508~~200,~~305~~287	$	~~606~~290,~~822~~380	$	2(223,~~285,380~~973	)	$	~~552~~(54,~~891~~185	)
Denominator:
Basic and diluted weighted average ordinary shares outstanding		15,449,000		3,737,500		15,449,000			3,737,500
Basic and diluted net income (loss) per ordinary share	$	0.1608	$	0.1608	$	(0.1501	)	$	(0.1501	)

	For the Three Months Ended September 30, 2021						For the period from February 22, 2021 (inception) through September 30, 2021
	Class A			Class B			Class A			Class B
Basic and diluted net income (loss) per ordinary share:
Numerator:
Allocation of net income (loss)	$	(272,914	)	$	(76,329	)	$	(234,014	)	$	(131,721	)
Denominator:
Basic and diluted weighted average ordinary shares outstanding		13,098,065			3,663,315			6,116,863			3,443,020
Basic and diluted net income (loss) per ordinary share	$	(0.02	)	$	(0.02	)	$	(0.04	)	$	(0.04	)

Recent Accounting Pronouncements

~~Management~~The Company’s management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed financial statements.

Note 3 - Initial Public Offering

On July 15, 2021, the Company consummated its Initial Public Offering of 14,950,000 Public Shares, including the 1,950,000 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $149.5 million, and incurring offering costs of approximately $8.7 million, inclusive of approximately $5.2 million in deferred underwriting commissions. On August 8, 2022, the Company received a waiver from one of ~~its~~the underwriters of its Initial Public Offering pursuant to which such underwriter waived all rights to its 50% share of the deferred underwriting commissions payable upon completion of an initial Business Combination. ~~In connection with this waiver, the underwriter also agreed that~~ (i)see ~~this~~Note waiver is not intended to allocate its 50% portion of the deferred underwriting commissions to the other underwriter that has not waived its right to receive its share of the deferred underwriting commissions and (ii1) the waived portion of the deferred underwriting commissions can, at the discretion of the Company, be paid to one or more parties or otherwise be used in connection with an initial Business Combination.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Note 4 - Related Party Transactions

Founder Shares

On March 18, 2021, the Sponsor paid $25,000 to cover certain of the Company’s expenses in exchange for the issuance of 3,737,500 Class B ordinary shares, par value $0.0001 (the “Founder Shares”). In June 2021, the Sponsor transferred an aggregate of 120,000 Founder Shares to the Company’s independent directors. The Sponsor agreed to forfeit up to 487,500 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters, so that the Founder Shares would represent 20.0% of the Company’s issued and outstanding ordinary shares (excluding the Private Placement Shares) after the Initial Public Offering. On July 15, 2021, the underwriters fully exercised the over-allotment option to purchase additional 1,950,000 Public Shares. As a result, the 487,500 Class B ordinary shares were no longer subject to forfeiture.

The initial shareholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.

Private Placement Shares

Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 499,000 Private Placement Shares, at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.0 million. Certain proceeds from the Private Placement Shares were added to the proceeds from the Initial Public Offering held in the Trust Account. ~~The Private Placement Shares were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.~~

The Private Placement Shares are not transferable or salable until 30 days after the completion of the initial Business Combination. ~~The~~ Certain proceeds from the Private Placement Shares have been added to the proceeds from the Initial Public Offering held in the Trust Account. The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Shares until 30 days after the completion of the initial Business Combination.

Related Party Loans

On March 31, 2021, a related party advanced approximately $1,400 to cover for certain expenses on behalf of the Company. The Company fully repaid the advance from related party of approximately $1,400 on April 5, 2021.

On March 18, 2021, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover for expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan was non-interest bearing and payable upon the completion of the Initial Public Offering. The Company borrowed $150,000 under the Note and fully repaid the Note amount on July 15, 2021. Subsequent to the repayment, the loan facility was no longer available to the Company.

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon the consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into shares of the post Business Combination entity at a price of $10.00 per share. The shares would be identical to the Private Placement Shares. As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, the ~~the~~ Company had no outstanding borrowings under the Working Capital Loans.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Administrative Support Agreement

Commencing on the date that the Company’s registration statement relating to its Initial Public Offering was declared effective through the earlier of consummation of the initial Business Combination and the Company’s liquidation, the Company agreed to reimburse the Sponsor for office space, secretarial and administrative services provided to the Company in the amount of $10,000 per month. For the three months ended ~~September~~March 3031, ~~2022~~2023 and ~~2021~~2022, the Company incurred expenses of approximately $30,000 ~~and~~ ~~$26,000, respectively, under this agreement. For the nine months ended September 30, 2022 and for the period from February 22, 2021~~ (~~inception~~unaudited) ~~through~~and ~~September~~ $30, ~~2021, the Company incurred expenses of approximately $90,~~000 ~~and $26~~(unaudited),~~000,~~ respectively, under this agreement. As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, the Company had $60120,000 (unaudited) and $090,000, respectively, in due to related party on the ~~condensed~~ balance sheets.

Note 5 - Commitments and Contingencies

Registration Rights

The holders of Founder Shares, Private Placement Shares, as well as the Private Placement Shares that may be issued upon conversion of Working Capital Loans, are entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the consummation of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the Founder Shares, in accordance with the letter agreement the Company’s initial shareholders entered into and (ii) in the case of the Private Placement Shares, 30 days after the completion of the Company’s Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriters a 45-day option from the final prospectus relating to the Initial Public Offering to purchase up to 1,950,000 additional Public Shares to cover over-allotments at the Initial Public Offering price less the underwriting discounts and commissions. On July 15, 2021, the underwriters fully exercised the over-allotment option.

On August 8, 2022, the Company received a waiver from one of ~~its~~the underwriters of its Initial Public Offering pursuant to which such underwriter waived all rights to its 50% share of the deferred underwriting commissions payable upon completion of an initial Business Combination. In connection with this waiver, the underwriter also agreed that (i) this waiver is not intended to allocate its 50% portion of the deferred underwriting commissions to the other underwriter that has not waived its right to receive its share of the deferred underwriting commissions and (ii) the waived portion of the deferred underwriting commissions can, at the discretion ~~discretion~~ of the Company, be paid to one or more parties or otherwise be used in connection with an initial Business Combination. ~~This~~During ~~waiver~~the ~~resulted~~year inended aDecember ~~gain~~31, ~~from~~2022, ~~settlement~~the Company derecognized approximately $2.6 million of the deferred underwriting commissions and recorded an adjustment to the carrying value of the shares of Class A ~~approximately~~ordinary ~~$2.6~~shares ~~million~~subject to possible redemption.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Risks and Uncertainties

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of the accompanying unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. The impact of this action and related sanctions on the world economy, as well as any specific impact on the Company’s financial condition, results of operations, and cash flows, is not determinable as of the date of these unaudited condensed financial statements.

Note 6 - Class A Ordinary Shares Subject to Possible Redemption

The Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, there were 14,950,000 Class A ordinary shares subject to possible redemption.

The Public Shares issued in the Initial Public Offering and in connection with the exercise by the underwriters of the over-allotment option were recognized in Class A ordinary shares subject to possible redemption as follows:

Gross Proceeds	$	149,500,000
Gross proceeds	$	149,500,000
Less:
Offering costs allocated to Class A ordinary shares subject to possible redemption		(8,709,154	)
Plus:
Accretion on Class A ordinary shares subject to possible redemption amount		8,709,154
Waiver of deferred underwriting commission		2,616,250
Class A ordinary shares subject to possible redemption at December 31, 2021		149,500,000
Accretion on Class A ordinary shares subject to possible redemption amount		8,094,625
Increase in redemption value of Class A ordinary shares subject to possible redemption		780,215
Class A ordinary shares subject to possible redemption at December 31, 2022		151,501,721
Class A ordinary shares subject to possible redemption at September 30, 2022	$	150,280,215
Plus:
Accretion on Class A ordinary shares subject to possible redemption amount		1,692,535
Class A ordinary shares subject to possible redemption at March 31, 2023	$	153,194,256

Note 7 - Shareholders’ ~~Equity (~~Deficit)

Preference Shares - The Company is authorized to issue 1,000,000 preference shares with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, there were no preference shares issued or outstanding.

Class A Ordinary Shares - The Company is authorized to issue 479,000,000 Class A ordinary shares with a par value of $0.0001 per share. ~~Holder~~Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, there were 15,449,000 Class A ordinary shares issued and outstanding, of which 14,950,000 shares were subject to possible redemption and classified in temporary equity, respectively (see Note 6).

Class B Ordinary Shares - The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, there were 3,737,500 Class B ordinary shares issued and outstanding (see Note 4).

Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law.

The Class B ordinary shares will automatically convert into Class A ordinary shares on the first business day following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares) upon the consummation of the Initial Public Offering, plus (ii) the sum of the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Shares issued to the Sponsor, members of the Company’s management team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one.

Table of Contents

ARYA SCIENCES ACQUISITION CORP V

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Note 8 - Fair Value Measurements

The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022 and ~~and~~ indicate the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.

~~September~~March 3031, ~~2022~~ 2023

Description

Quoted Prices in Active Markets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Other Unobservable Inputs (Level 3)

Assets held in Trust Account

Investments held in Trust Account

U.S. Treasury Securities

~~150~~153,~~371~~293,~~360~~384

-—

Cash equivalents - money market funds

~~8,855~~872

-—

~~150~~153,~~380~~294,~~215~~256

-—

December 31, ~~2021~~2022

Description

Quoted Prices in Active Markets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Other Unobservable Inputs (Level 3)

Assets held in Trust Account

Investments held in Trust Account

U.S. Treasury Securities

~~149~~151,~~523~~592,~~037~~810

-—

Cash equivalents - money market funds

78,~~477~~911

-—

~~149~~151,~~530~~601,~~514~~721

-—

Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period. There were no transfers between levels of the hierarchy for the three ~~nine~~ months ended ~~September~~March 3031, ~~2022~~2023 orand ~~for~~ the ~~period~~year ~~from~~ended ~~February~~December 2231, ~~2021 (inception) through September 30, 2021~~2022. Level 1 instruments include investments U.S. Treasury securities with an original maturity of 185 days or less.

Note 9 - Subsequent Events

The Company evaluated subsequent events and transactions that occurred up to the date the unaudited condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.

Table of Contents

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

References to the “Company,” “ARYA Sciences Acquisition Corp V,” “ARYA,” “our,” “us” or “we” refer to ARYA Sciences Acquisition Corp V. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited interim condensed financial statements and the notes thereto contained elsewhere in this Quarterly Report on Form 10-Q (this “Report”). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

Some of the statements contained in this Report may constitute “forward-looking statements” for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this Report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following risks, uncertainties (some of which are beyond our control) or other factors:

•	we have no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective;

•	our ability to select an appropriate target business or businesses;

•	our ability to complete a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”);

•	our expectations around the performance of a prospective target business or businesses;

•	our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial Business Combination;

•	our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial Business Combination;

• our potential ability to obtain additional financing to complete our initial Business Combination or reimburse any loans ARYA Sciences Holdings V (the “Sponsor”) may loan to the Company (the “Working Capital Loans”);

•	our pool of prospective target businesses;

• our ability to consummate an initial Business Combination due to the uncertainty resulting from general economic and political conditions such as recessions, interest rates, international currency fluctuations and health epidemics and pandemics (including the ongoing COVID-19 pandemic), inflation, changes in diplomatic and trade relationships and acts of war or terrorism (such as the military conflict between Ukraine, the Russian Federation and Belarus that started in February 2022);

•	the ability of our officers and directors to generate a number of potential Business Combination opportunities;

•	our ability to obtain additional financing to complete a Business Combination;

•	our public securities’ potential liquidity and trading;

• the use of proceeds not held in the trust account (“Trust Account”) or available to us from interest income on the ~~trust~~Trust ~~account~~Account balance;

• ~~the~~our ~~trust~~ability ~~account not being subject~~ to ~~claims~~continue ofas ~~third~~a ~~parties;~~going concern

• ~~our~~the ~~financial~~Trust ~~performance~~Account ~~following~~not ~~our~~being ~~initial~~subject ~~public~~to ~~offering~~claims ~~(the~~of ~~“Initial~~third ~~Public Offering”)~~parties; ~~and~~

• ~~the other risks and uncertainties discussed herein and in~~ our ~~filings~~financial ~~with~~performance ~~the~~following ~~SEC, including~~ our ~~Annual~~initial ~~Report~~public onoffering ~~Form 10-K filed with~~ (the ~~SEC~~“Initial onPublic ~~March 31, 2022.~~Offering”);

•	the amount of redemptions by our public shareholders in connection with a proposed Business Combination; and

•	the other risks and uncertainties discussed herein and in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on April 12, 2023.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Table of Contents

Overview

We are a blank check company incorporated as a Cayman Islands exempted company on February 22, 2021. We were formed for the purpose of effecting a Business Combination that we have not yet identified. Our ~~sponsor~~Sponsor is ARYA Sciences Holdings V, a Cayman Islands exempted limited company ~~(the “Sponsor”)~~.

Our registration statement for our Initial Public Offering was declared effective on July 12, 2021. On July 15, 2021, we consummated its Initial Public Offering of 14,950,000 Class A ordinary shares (the “Public Shares”), including the 1,950,000 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $149.5 million, and incurring offering ~~offering~~ costs of approximately $8.7 million, inclusive of approximately $5.2 million in deferred underwriting commissions. On August 8, 2022, the Company received a waiver from one of ~~its~~the underwriters of its Initial Public Offering pursuant to which such underwriter waived all rights to its 50% share of the deferred underwriting commissions payable upon completion of an initial Business Combination (the “Waiver”). In connection with this ~~waiver~~Waiver, the underwriter also agreed that (i) this ~~waiver~~Waiver is not intended to allocate its 50% portion of the deferred underwriting commissions to the other underwriter that has not waived its right to receive its share of the deferred underwriting commissions and (ii) the waived portion of the deferred underwriting commissions can, at the discretion of the Company, be paid to one or more parties or otherwise be used in connection with an initial Business Combination.

Simultaneously with the closing of the Initial Public Offering, we consummated the private placement (“Private Placement”) of 499,000 Class A ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.0 million ~~(Note 4)~~.

Upon the closing of the Initial Public Offering and the Private Placement, $149.5 million ($10.00 per Public Share) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement were placed in athe ~~trust account (“~~Trust Account”), located in the United States, with Continental Stock Transfer & Trust Company acting as trustee, and are invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.

Our management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.

If we have not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

Table of Contents

We intend to effectuate our initial Business Combination using cash from the proceeds of our Initial Public Offering and the sale of the Private Placement Shares, our shares, debt or a combination of cash, equity and debt.

The issuance of additional shares in a Business Combination:

•

may significantly dilute the equity interest of investors in our Initial Public Offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares;

•

may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares;

•

could cause a change in control if a substantial number of our Class A ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;

•

may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and

•

may adversely affect prevailing market prices for our Class A ordinary shares.

Similarly, if we issue debt or otherwise incur significant debt, it could result in:

•

default and foreclosure on our assets if our operating revenues after an initial Business Combination are insufficient to repay our debt obligations;

•

acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;

•

our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand;

•

our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;

•

our inability to pay dividends on our Class A ordinary shares;

•

using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary shares if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;

•

limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;

•

increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and

•

limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

Results of Operations

Our entire activity since inception up to ~~September~~March 3031, ~~2022~~2023 was in preparation for our formation and the Initial Public Offering, and since the Initial Public Offering, the search for a ~~business~~prospective ~~combination~~initial ~~target~~Business Combination. We will not be generating any operating revenues until the closing and completion of our initial Business Combination.

For the three months ended ~~September~~March 3031, ~~2022~~2023, we had net income of approximately $3.1.5 million, which consisted of approximately $21.67 million in ~~gain from settlement of deferred underwriting commissions and approximately $662,000 in~~ unrealized gains on marketable securities, dividends and interest held in Trust Account, which were partially offset by approximately $~~163~~202,000 general and administrative expenses.

For the three months ended ~~September~~March 3031, ~~2021~~2022, we had net loss of approximately $~~349~~278,000, which consisted of general and administrative expenses of $~~364~~228,000, ~~partially~~and ~~offset~~an by unrealized ~~gain~~loss on investments of approximately $1550,000.

For the nine months ended September 30, 2022, we had net income of approximately $2.8 million, which consisted of approximately $2.6 million in gain from settlement of deferred underwriting commissions and approximately $850,000 in unrealized gains on marketable securities, dividends and interest held in Trust Account, which were partially offset by approximately $627,000 general and administrative expenses.

For the period from February 22, 2021 (inception) through September 30, 2021, we had net loss of approximately $366,000, which consisted of general and administrative expenses of $380,000, partially offset by unrealized gain on investments of $14,000.

Table of Contents

Going Concern

As of ~~September~~March 3031, ~~2022~~2023, we had approximately $~~419~~296,000 in our operating bank account, and working capital deficit of approximately $2.16 million.

Our liquidity needs to date have been satisfied through a contribution of $25,000 from the Sponsor to cover for certain ~~offering~~expenses ~~costs~~ in exchange for the issuance of the Founder Shares, the loan of approximately $151,000 from the Sponsor pursuant to the ~~Note~~$300,000 ~~(as~~unsecured, ~~defined~~non-interest inbearing ~~Note~~promissory 4)note ~~and~~(the ~~advances~~“Note”) ~~from~~that the Sponsor agreed to advance to the Company, and $2 million in proceeds from the consummation of the Private Placement not held in the Trust Account. We fully repaid the Note on July 15, 2021. Subsequent to the repayment, the loan facility was no longer available to us. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of our officers and directors may, but are not obligated to, provide the Company Working Capital Loans. As of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, there were no amounts outstanding under any Working Capital Loan.

We cannot provide any assurance that new financing along the lines detailed above will be available to us on commercially acceptable terms, if at all. Further, we have until July 15, 2023 to consummate a Business Combination, but we cannot provide assurance that we will be able to consummate a Business Combination by that date. If a Business Combination is not consummated by the required date, there will be a mandatory liquidation and subsequent ~~subsequent~~ dissolution. In connection with our assessment of going concern considerations in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, “Basis of Presentation - Going Concern,” we have determined that the working capital deficit and mandatory liquidation and subsequent dissolution raises substantial doubt about our ability to continue as a going concern until the earlier of the consummation of the Business Combination or the date we are required to liquidate. The unaudited condensed financial statements do not include any adjustment that might be necessary if wethe ~~are~~Company is unable to continue as a going concern. We intend to complete our initial ~~business~~Business Combination ~~combination~~ before the mandatory liquidation date; however, there can be no assurance that we will be able to consummate any ~~business~~Business ~~combination~~Combination by July 15, 2023. No adjustments have been made to the carrying amounts of assets and liabilities should we be required to liquidate after July 15, 2023, nor do these unaudited condensed financial statements include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should we be unable to continue as a going concern.

~~Management~~Risks ~~continues to evaluate the impact of the COVID-19 pandemic on the industry~~ and has concluded that while it is reasonably possible that the virus could have a negative effect on our financial position, results of our operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statements included in this Report. The financial statements included in this Report do not include any adjustments that might result from the outcome of this uncertainty.Uncertainties

InResults ~~February~~of ~~2022,~~operations and the ~~Russian~~Company’s ~~Federation~~ability ~~and~~to ~~Belarus~~complete ~~commenced~~ a ~~military~~Business ~~action~~Combination ~~with~~may be adversely affected by various factors that could cause economic uncertainty and volatility in the ~~country~~financial markets, many of which ~~Ukraine~~are beyond its control. AsThe aCompany’s ~~result~~business of ~~this~~pursuing ~~action~~and consummating an initial Business Combination could be impacted by, ~~various~~among ~~nations~~other things, ~~including~~downturns in the ~~United~~financial ~~States~~markets or in economic conditions, ~~have~~export ~~instituted~~controls, tariffs, ~~economic~~trade ~~sanctions~~wars, ~~against~~inflation, ~~the~~increases ~~Russian~~in ~~Federation~~interest rates, supply chain disruptions, declines in consumer confidence and ~~Belarus.~~spending, ~~The~~the ~~impact~~ongoing effects of ~~this~~the ~~action~~COVID-19 ~~and~~pandemic, ~~related~~including ~~sanctions~~resurgences onand the ~~world~~emergence ~~economy~~of new variants, asand ~~well~~geopolitical instability, such as ~~any~~the ~~specific~~military ~~impact~~conflict onin the Ukraine. The Company’s ~~financial~~cannot ~~condition,~~at ~~results~~this time fully predict the likelihood of ~~operations,~~one ~~and~~or ~~cash~~more ~~flows~~of the above events, ~~are~~their ~~not~~duration or magnitude or the extent to which they may materially impact the Company’s ~~determinable~~business asand ofits ~~the~~ability ~~date~~to ofcomplete ~~this~~an ~~Report~~initial Business Combination.

Contractual Obligations

Administrative Support Agreement

Commencing on the effective date of the registration statement on Form S-1 related to the Initial Public Offering through the earlier of consummation of the initial Business Combination and our liquidation, we ~~agreed to~~ reimburse the Sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. For the three months ended September 30, 2022 and 2021, we incurred expenses of approximately $30,000 and $26,000, respectively, under this agreement. For the nine months ended September 30, 2022 and for the period from February 22, 2021 (inception) through September 30, 2021, we incurred expenses of approximately $90,000 and $26,000, respectively, under this agreement. As of September 30, 2022 and December 31, 2021 we had $60,000 and $0, respectively, in due to related party on the condensed balance sheets.

We incurred approximately $30,000 and $30,000 in general and administrative expenses in the accompanying unaudited condensed statements of operations for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023 and December 31, 2022, the Company had $120,000 (unaudited) and $90,000, respectively, included in due to related party on the balance sheets.

Table of Contents

Registration Rights

The holders of Founder Shares, Private Placement Shares, ~~and~~including Private Placement Shares that may be issued upon conversion of Working Capital Loans, are entitled to registration rights pursuant to a registration ~~registration~~ and shareholder rights agreement signed upon the consummation of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our completion of a Business Combination. However, the registration and shareholder rights agreement provides that ~~the Company~~we will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the Founder Shares, in accordance with the letter agreement that our initial shareholders entered into and (ii) in the case of the Private Placement Shares, 30 days after the completion of our Business Combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

We granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 1,950,000 additional Public Shares to cover over-allotments at the Initial Public Offering price less the underwriting discounts and commissions. On July 15, 2021, the underwriters fully exercised the over-allotment option.

The underwriters were paid an underwriting discount of $0.20 per Public Share, or approximately $3.0 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per Public Share, or approximately $5.2 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement. On August 8, 2022, the Company received a waiver from one of ~~its~~the underwriters of its Initial Public Offering pursuant to which such underwriter waived all rights to its 50% share of the deferred underwriting commissions payable upon completion of an initial Business Combination. In connection with ~~this~~the ~~waiver~~Waiver, the underwriter also agreed that (i) this ~~waiver~~Waiver is not intended to allocate its 50% portion of the deferred underwriting commissions to the other underwriter that has not waived its right to receive its share of the deferred underwriting commissions and (ii) the waived portion of the deferred underwriting commissions can, at the discretion of the Company, be paid to one or more parties or otherwise be used in connection with an initial Business Combination. ~~This waiver resulted in a gain from settlement of deferred underwriting commissions of approximately $2.6 million.~~

Critical Accounting Estimates

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses during the period reported. Actual results could materially differ from those estimates. The Company has not identified any critical accounting estimates.

Critical Accounting Policies

Class A ordinary shares subject to possible redemption

We account for our Class A ordinary shares subject to possible redemption in accordance with the guidance in FASB ASC Topic 480, “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ ~~equity (~~deficit). Our Class A ordinary shares feature certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, as of ~~September~~March 3031, ~~2022~~2023 and December 31, ~~2021~~2022, 14,950,000 Class A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ ~~equity (~~deficit) section of our condensed balance sheets.

Table of Contents

Net income (loss) per ordinary share

We have two classes of shares: Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of ordinary shares outstanding during the periods. Accretion associated with the Class A ordinary shares subject to possible redemption is excluded from earnings per share as the redemption value approximates fair value.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed financial statements.

Off-Balance Sheet Arrangements

As of ~~September~~March ~~30, 2022 and December~~ 31, ~~2021~~2023, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

JOBS Act

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting ~~accounting~~ standards, and, as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the ~~financial~~unaudited ~~statements~~condensed ~~may~~financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the executive compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in Company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Table of Contents

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of ~~September~~March 3031, ~~2022~~2023 (the “Evaluation Date”). Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective because we identified a material weakness in our internal control over financial reporting in connection with the preparation of our Annual Report on Form 10-K for the year ended December 31, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, the Company’s management has concluded that our control around the interpretation and accounting for extinguishment of a significant contingent obligation in connection with the Waiver was not effectively designed or maintained. Historically, the Company had recognized a liability upon closing of its Initial Public Offering in July 2021 for a portion of the deferred underwriting commissions which was contingently payable upon closing of a future business combination, with the offsetting entry resulting in an initial discount to the securities sold in the Initial Public Offering. In its previously issued unaudited condensed financial statements as of and for the period ended September 30, 2022, the Company recognized the Waiver as an extinguishment, with a resulting non-operating gain recognized in its statement of operations. Upon subsequent review and analysis, management concluded that the Company should have recognized the extinguishment of the contingent liability as a credit to shareholders’ deficit.

In ~~2021,~~light ~~our~~of ~~management~~this ~~and audit committee identified a~~ material weakness, ~~in our internal control over financial reporting that resulted in~~ the ~~restatement~~Company ofperformed ~~our~~additional ~~audited~~analysis ~~balance sheet~~ as ofdeemed ~~July~~necessary ~~15, 2021~~to inensure ~~our Annual Report on Form 10-K for the year ended December 31, 2021. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such~~ that ~~there is a reasonable possibility that a material misstatement of~~ our ~~annual or interim~~ financial statements ~~will~~were ~~not~~prepared bein ~~prevented~~accordance orwith ~~detected on a timely basis~~GAAP. ~~Specifically~~Accordingly, ~~our~~ management ~~and~~believes ~~audit committee concluded~~ that ~~the control around the interpretation and accounting of our~~ ~~Class~~the Afinancial ~~ordinary~~statements ~~shares~~included ~~was~~in ~~not effectively designed or maintained. In connection with the remediation of~~ this ~~control~~Report ~~deficiency,~~present ~~management~~fairly ~~and~~in ~~its~~all ~~advisors~~material ~~designed~~respects ~~and implemented new disclosure controls and procedures and expanded and improved~~ our ~~processes~~financial to ensure that the nuances of the accounting of certain complex features of our Class A ordinary shares are effectively evaluated in the context of increasingly complex accounting standards. Based on the actions takenposition, asresults ~~well as the evaluation~~ of ~~the~~operations ~~design of the new disclosure controls~~ and ~~procedures,~~cash weflows ~~previously~~for ~~concluded that our disclosure controls and procedures were operating effectively as of June 30, 2022 and that~~ the ~~material~~period ~~weakness we previously identified was remediated as of June 30, 2022~~presented.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we detected all of our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on the evaluation we conducted, our management has concluded that no such changes have occurred.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

None.

Item 1A.

Risk Factors

~~Except~~As ~~for the below risk factor, as~~ of the date of this Report, there have been no material changes to the risk factors disclosed in our ~~annual~~Annual ~~report~~Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on ~~March~~April 3112, ~~2022~~ 2023. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

Table of Contents

Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations.

We are subject to laws and regulations enacted by national, regional and local governments. In particular, we are required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our initial business combination, and results of operations.

On March 30, 2022, the SEC issued proposed rules relating to, among other items, enhancing disclosures in business combination transactions involving SPACs and private operating companies and increasing the potential liability of certain participants in proposed business combination transactions. These rules, if adopted, whether in the form proposed or in revised form, may materially increase the costs and time required to negotiate and complete an initial business combination and could potentially impair our ability to complete an initial business combination.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities.

~~Simultaneously~~Private ~~with~~Placements ~~the consummation of the Initial Public Offering~~ and the exercise of the over-allotment option by the underwriters in full, our sponsor purchased 499,000 Private Placement Shares, at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.0 million. A portion of the proceeds from the Private Placement Shares was added to the proceeds from the Initial Public Offering ~~held in the Trust Account.~~Proceeds

On March 18, 2021, we issued 3,737,500 of our Class B ordinary shares to our sponsor, in exchange for a capital contribution of $25,000, or approximately $0.007 per share. Such securities were issued in connection with our organization pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

Simultaneously with the consummation of the Initial Public Offering and the exercise of the over-allotment option by the underwriters in full, our sponsor purchased 499,000 Private Placement Shares, at a price of $10.00 per Private Placement Share to the Sponsor, generating gross proceeds of approximately $5.0 million. A portion of the proceeds from the Private Placement Shares was added to the proceeds from the Initial Public Offering held in the Trust Account. The Private Placement Shares were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

No underwriting discounts or commissions were paid with respect to the sales of the Class B ordinary shares or the private placement shares.

In connection with the Initial Public Offering, our sponsor had agreed to loan us an aggregate of up to $300,000 pursuant to the Note. This loan is non-interest bearing and payable on the consummation of the Initial Public Offering. The Company borrowed $150,000 under the Note and fully repaid the Note amount on July 15, 2021.

Use of Proceeds

Of the gross proceeds received from the Initial Public Offering and the full exercise of the option to purchase additional Shares, $149,500,000 was placed in the Trust Account. The net proceeds of the Initial Public Offering and certain proceeds from the Private Placement are invested in U.S. government treasury bills with a maturity of 180 days or less and in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations.

We paid a total of approximately $3.0 million in underwriting discounts and commissions related to the Initial Public Offering. In addition, the underwriters agreed to defer $5.2 million in underwriting discounts and commissions. On August 8, 2022, the Company received a waiver from one of its underwriters pursuant to which such underwriter waived all rights to its 50% share of the deferred underwriting commissions payable upon completion of an initial Business Combination. In connection with this waiver, the underwriter also agreed that (i) this waiver is not intended to allocate its 50% portion of the deferred underwriting commissions to the other underwriter that has not waived its right to receive its share of the deferred underwriting commissions and (ii) the waived portion of the deferred underwriting commissions can, at the discretion of the Company, be paid to one or more parties or otherwise be used in connection with an initial Business Combination. There has been no material change in the planned use of the proceeds from the Initial Public Offering and private placement as is described in the Company’s final prospectus relating to the Initial Public Offering.

Item 3.

Defaults upon Senior Securities

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

None.

Table of Contents

Item 6.

Exhibits.

The following exhibits are filed or furnished as a part of, or incorporated by reference into, this Report.

Exhibit Number		Description
3.1		Amended and Restated Memorandum and Articles of Association.(1)
4.1		Specimen Ordinary Share Certificate.(2)
10.1		Private Placement Shares Purchase Agreement between the Company and the Sponsor.(1)
10.2		Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Company.(1)
10.3		Registration and Shareholder Rights Agreement among the Company, the Sponsor and certain other equityholders named therein.(1)
10.4		Letter Agreement among the Company, the Sponsor and the Company’s officers and directors.(1)
10.5		Administrative Services Agreement between the Company and the Sponsor.(1)
10.6		Form of Indemnity Agreement.(2)
31.1		Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1		Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).*
101.SCH		Inline XBRL Taxonomy Extension Schema Document.*
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.*
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).*

*	Filed herewith.

**	Furnished herewith.

(1)	Incorporated by reference to the registrant’s Current Report on Form 8-K, filed with the SEC on July 15, 2021.

(2)	Incorporated by reference to the registrant’s Registration Statement on Form S-1, filed with the SEC on June 24, 2021.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 7, 2022	ARYA SCIENCES ACQUISITION CORP V
Dated: May 12, 2023	ARYA SCIENCES ACQUISITION CORP V
	By:	/s/ Michael Altman
	Name:	Michael Altman
	Title:	Chief Financial Officer

Filing Compare · ARYA Sciences Acquisition Corp V